OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Endocrinology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe	541
More than meets the eye: predicting adrenocortical carcinoma outcomes with pathomics	256
18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC Study	140
Metabolically healthy obesity was significantly associated with increased risk of gallstones	137
Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study	125
Thyroid hormone resistance index and mortality in euthyroid subjects: [email protected] study	97
Response to the letter of Hoermann and colleagues	73
Evaluation of a new transition organization for young adults with endocrine or metabolic diseases	67
Erratum to: “Adenylate cyclase stimulation and [3H]thymidine incorporation in human thyroid tissues and thyrocyte cultures: The effect of IgG preparation from patients with different thyroid disorders	64
Broad-spectrum XX and XY gonadal dysgenesis in patients with a homozygous L193S variant in PPP2R3C	64
Association of sleep and circadian patterns and genetic risk with incident type 2 diabetes: a large prospective population-based cohort study	59
Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes	57
Postgraduate training and continuous medical education in endocrinology in Europe	57
Differences between transient neonatal diabetes mellitus subtypes can guide diagnosis and therapy	55
Inflammatory biomarkers in the evaluation of pediatric endogenous Cushing syndrome	55
Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study	53
Durable biochemical response and safety with oral octreotide capsules in acromegaly	52
MECHANISMS IN ENDOCRINOLOGY: The gut–brain axis: regulating energy balance independent of food intake	51
Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience	47
Serum diiodotyrosine – a biomarker to differentiate destructive thyroiditis from Graves’ disease	44
Biallelic POC1A variants cause syndromic severe insulin resistance with muscle cramps	44
Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis	43
Overexpression of miR-7977 in CD4+ T cells is associated with multiplex autoimmunity in patients with Addison’s disease	40
Intramuscular fatty infiltration and physical function in controlled acromegaly	40
Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer	40

Prevalence and risk factors of hypothalamic–pituitary dysfunction in infant and toddler childhood brain tumor survivors	39
Correction to: Lack of NAD(P)+ transhydrogenase activity in patients with primary adrenal insufficiency due to NNT variants	39
Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study	39
Should patients with adult GH deficiency receive GH replacement?	37
International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry	35
High prevalence of variants in skeletal dysplasia associated genes in individuals with short stature and minor skeletal anomalies	32
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity	32
Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register	32
Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study	32